Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677618 | 0.75 | BRD4 (0.50) | CYP11B2BRD4CREBBP | |
| SCHEMBL1450858 | 0.73 | PKM (0.37) | GAA | |
| SCHEMBL1500107 | 0.73 | PARP1 (0.35) | BRD4CREBBP | |
| SCHEMBL3483234 | 0.73 | TRIM24 (0.39) | GAA | |
| SCHEMBL18000490 | 0.73 | DDB1 (0.38) | BRD4CREBBP | |
| SCHEMBL213748 | 0.72 | MAOA (0.40) | — | |
| SCHEMBL3755745 | 0.70 | BRD4 (0.59) | BRD4CREBBP | |
| SCHEMBL20400573 | 0.70 | CYP1A2 (0.50) | — | |
| SCHEMBL7838919 | 0.69 | CYP2A6 (0.54) | CYP11B2 | |
| SCHEMBL5985141 | 0.69 | CYP11B2 (0.45) | CYP11B2GAASMN1; SMN2NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238683-B2 | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-07-03 | — | — | US | claimed |
| US-20060281727-A1 | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-12-14 | — | — | US | claimed |
| US-7238683-B2 | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060281727-A1 | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281727-A1 | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | CYP11B2 2179/4885GAA 151/4885SMN1; SMN2 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.